FXI substrate cleavage sequences, separated by physiological process
| Pathway . | FXIa substrate . | Cleavage sequence . | Reference . |
|---|---|---|---|
| Coagulation | FIX | KLTR145-AET DFTR180-VVG | 75,76 |
| FVIII | IQIR372-SVA IEPR740-SFS EITR1652-TTL LRNR1740-AQS | 77 | |
| FV | KKYR348-SQH GIQR510-AAD SSWR1765-LTS | 25,77 | |
| FX | NNLTR234-IVG | 25,29 | |
| TFPI | RIIK86-TTL GICR107-GYI GLCR199-ANE | 78 | |
| Platelet activation | ADAMTS13 | Unknown | 79 |
| KKS | FXII | SMTR372-VVG | 80 |
| HK | SLMK380-RPP SPFR389-SSR | 81 | |
| Inflammation | CFH | ENMR341-RPY | 82 |
| β2GPI | AFWK336-TDA | 83 | |
| Properdin | Unknown | 84 | |
| Chem163S | AFSK158-ALP | 85 | |
| HGF | DLHR424-HIF KQLR494-VVN | 86 |
| Pathway . | FXIa substrate . | Cleavage sequence . | Reference . |
|---|---|---|---|
| Coagulation | FIX | KLTR145-AET DFTR180-VVG | 75,76 |
| FVIII | IQIR372-SVA IEPR740-SFS EITR1652-TTL LRNR1740-AQS | 77 | |
| FV | KKYR348-SQH GIQR510-AAD SSWR1765-LTS | 25,77 | |
| FX | NNLTR234-IVG | 25,29 | |
| TFPI | RIIK86-TTL GICR107-GYI GLCR199-ANE | 78 | |
| Platelet activation | ADAMTS13 | Unknown | 79 |
| KKS | FXII | SMTR372-VVG | 80 |
| HK | SLMK380-RPP SPFR389-SSR | 81 | |
| Inflammation | CFH | ENMR341-RPY | 82 |
| β2GPI | AFWK336-TDA | 83 | |
| Properdin | Unknown | 84 | |
| Chem163S | AFSK158-ALP | 85 | |
| HGF | DLHR424-HIF KQLR494-VVN | 86 |
FXIa has a preference for cleaving substrates at peptide bonds between arginine or lysine and alanine, valine, or serine residues. To a lesser extent, FXIa can also cleave between arginine or lysine and threonine or arginine residues.
CFH, complement factor H; Chem163S, prochemerin; HGF, heptaocyte growth factor; KKS, kallikrein-kinin system; TFPI, tissue factor pathway inhibitor.